Testing of the anti-CD20 monoclonal antibody in elderly patients with lymphocytic leukaemia (median age 69 years) in a phase III clinical trial has demonstrated that treatment with ofatumumab plus chlorambucil compared with chlorambucil alone results in significantly improved progression-free survival (median 22.4 months versus 13.1 months; P <0.001). More adverse events were detected in the ofatumumab plus chlorambucil group (50% versus 43%). Results suggest this regimen is effective in elderly patients.
References
Hillmen, P. et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 10.1016/S0140-6736(15)60027-7
Rights and permissions
About this article
Cite this article
Ofatumumab is effective in elderly patients. Nat Rev Clin Oncol 12, 374 (2015). https://doi.org/10.1038/nrclinonc.2015.84
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.84
